Intellia Therapeutics (NTLA) Other Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 64.82% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 64.82% decrease from a year earlier, with the FY2025 full-year figure at $978000.0, down 74.18% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.1 million, up from $978000.0 in the prior quarter.
• Over the last five years, Other Non-Current Assets for NTLA reached as high as $4.5 million in Q4 2023 and fell as low as $978000.0 in Q4 2025.
• Historically, Other Non-Current Assets has averaged $3.0 million across 4 years, with a median of $3.2 million in 2024.
• On a YoY basis, Other Non-Current Assets climbed as much as 10.58% in 2025 and fell as far as 74.18% in 2025.
• Year by year, Other Non-Current Assets stood at $4.5 million in 2023, then declined by 16.16% to $3.8 million in 2024, then sank by 74.18% to $978000.0 in 2025, then climbed by 7.57% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $1.1 million in Q1 2026, $978000.0 in Q4 2025, and $2.9 million in Q3 2025.